The “Drop Pop” X account, a satirical parody account that looks similar to actual news accounts, is behind the false claims ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

But a Lake Worth scientist and inventor has a product on the market that he says helps athletes deal with and prevent ...

智通财经APP获悉，吉利德科学(GILD.US)今日公布其每半年注射一次的艾滋病毒衣壳抑制剂lenacapavir用于预防艾滋病毒(HIV)感染的第二项关键3期试验PURPOSE 2的全部结果。分析显示，接受lenacapavir的受试者中，高达99.9%未感染艾滋病毒，且其预防艾滋病毒感染的效果，优于现有每日一次口服疗法。详细数据公布于艾滋病毒感染药物治疗国际大会，并将发表在《新英格兰医学杂志》 ...

吉利德科学 (GILD.US)今日公布其每半年注射一次的艾滋病毒衣壳抑制剂lenacapavir用于预防艾滋病毒 (HIV)感染的第二项关键3期试验PURPOSE ...

As a former trial attorney with more than a decade of litigation experience, Jamie L. Pfeiffer writes trustworthy, engaging ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...